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Abstract
Accurate clinical staging of oral squamous cell cancer can be quite difficult to achieve especially if nodal
involvement is identified. Radiologically-assisted clinical staging is more accurate and informs the clinician of loco-
regional and distant metastasis.
In this study, we compared clinical TNM (cTNM) staging (not including ultrasonography) to pathological TNM
(pTNM) staging in 245 patients presenting with carcinoma of the oral cavity and the oro-pharyngeal region.
Tumour size differences and nodal involvement were highlighted. US reports of the neck were then added to the
clinical staging and results compared.
Tumour size was clinically underestimated in 4 T1, 2 T2 and 2 T3 oral diseases. Also 20 patients that were reported
as nodal disease free had histological proven N1 or N2 nodal involvement; while 3 patients with cTNM showing
N1 disease had histologically proven N2 disease.
Overall the agreement between the 2 systems per 1 site was 86.6% (Kappa agreement = 0.80), per 2 sites 90.0%
(Kappa agreement = 0.68) and per 3 sites 90.5% (Kappa agreement 0.62).
An accurate clinical staging is of an utmost importance. It is the corner stone in which the surgical team build the
surgical treatment plan and decide whether an adjuvant therapy is required to deal with any possible problem
that might arise. The failure to achieve an accurate staging may lead to incomplete surgical planning and hence
unforeseen problems that may adversely affect the patient’s survival.
Background
The development of modern imaging techniques has
significantly altered the treatment and management of
head and neck malignancies. Important treatment deci-
s i o n st h a tw e r eo n c em a d ei n t r a - o p e r a t i v e l ya r en o w
made preoperatively by means of advanced imaging, i.e.
computed tomography (CT) and magnetic resonance
imaging (MRI) [1].
MRI has been proved superior to CT, on account of
its coronal and sagittal slice orientation enabling not
only a better demonstration of findings, but also
improved tumour detection and staging [2]. Also when
it comes to T-staging, MRI is overall more accurate
than CT. However, if degraded images and T1 tumours
are excluded, the techniques are comparable. MRI is
oversensitive for recurrent disease. For Nodal staging,
MRI was found comparable to CT [3]. Although CT
and MRI allow detection of abnormally enlarged nodes
or necrotic nodes, neither borderline-sized nodes with-
out necrosis nor extra-capsular spread are reliably differ-
entiated from reactive or normal nodes in patients with
head and neck cancer [4].
Accurate clinical staging of pathologies involving the
oral and oro-pharyngeal-laryngeal regions can be quite
difficult to achieve, especially if nodal disease is
involved. The current practice worldwide when it comes
to clinically staging tumours identified in these areas
usually involve carrying out a thorough clinical examina-
tion of the head and neck region followed by radiologi-
cal investigations. The latter usually involve carrying out
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invasion is anticipated (i.e. edentulous patients). The
rest of the clinical staging involve a CT scanning of the
chest and the upper abdomen to rule out any tumour
spread to the pulmonary or hepato-pancreato-biliary
organs [5].
In most of the centres in the developed world, an
ultrasonography (US) imaging of the neck is carried out
to identify any nodal involvement which cannot be iden-
tified by other imaging modalities (i.e. MRI or CT);
unfortunately the lack of expertise in the developing
world stops the application of US technology. US is a
reliable and valuable tool for metastatic lymph node
screening in head and neck cancer patients. It is a
cheap, non-invasive, easy-to-handle and cost-effective
diagnostic method [6].
This has lead many centres around the world to
change its practice to include US as part of clinical sta-
ging process for any patient who presents with patholo-
gical lesion in the head and neck. Furthermore, the
advances in cytological sciences allowed fine needle
aspiration of neck nodes under US-guidance and
allowed identification of reactive lymph nodes prior to
surgery. A study identified US, with or without FNAC,
as an accurate (86%), sensitive (92%) and specific (83%)
technique for the preoperative assessment of lymph
node metastases in patients with SCC [7]. In another
study, US (for all levels) yielded a sensitivity of 71%, and
a specificity of 87%, while CT showed a sensitivity of
32% and a specificity of 96%. The sensitivity of US
decreased from level I to level IV, whereas the specificity
increased from level I to level IV [8].
In this short communication, we retrospectively com-
pared clinical TNM (cTNM) staging (not including US)
to pathological TNM (pTNM) staging in patients pre-
senting with carcinoma of the oral cavity and the oro-
pharyngeal region. Tumour size differences and nodal
involvement were highlighted. US reports of the neck
were then added to the clinical staging and results
compared.
Materials & methods
In this retrospective analytic study, we looked at cTNM
staging and pTNM staging of 245 patients with oral and
pharyngeal squamous cell carcinoma who underwent
treatment at the UCLH Head and Neck Centre, London
from 2001 to 2006.
The patients’ data were entered onto proformas, which
were validated and checked by interval sampling. The
fields included a range of clinical, operative and histo-
pathological variables related to disease staging. All
applications were accompanied by multidisciplinary
team recommendation, ethical approval and informed
patient consent.
In this short communication, the cTNM staging was
achieved through clinical examination of the head and
neck region and MRI, or CT scan when indicated, and
no US scan of the neck. This was compared to pTNM
trying to identify any underestimation in tumour size or
missed cervical nodal disease. Agreement between both
staging systems were assessed per anatomical site. Then,
US reports were added to the cTNM staging and results
compared again.
Statistical analysis
The outcomes of the categorical clinic-pathological vari-
ables (cTNM and pTNM) were summarised as frequen-
cies and percentages for the whole group of patients.
Kappa score agreement, with its standard error, was cal-
culated to compare cTNM and pTNM for primary, sec-
ondary and tertiary sites; also was applied to per 1 site,
per 2 sites and per 3 sites.
Results
T a b l e1h i g h l i g h t st h ec T N Ma n dt h ep T N Ms t a g i n go f
the cohort involved in this study. Tumour size was clini-
cally underestimated in 4 T1, 2 T2 and 2 T3 oral dis-
eases. Also 20 patients that were reported as nodal
disease free had histological proven N1 or N2 nodal
involvement; while 3 patients with cTNM showing N1
disease had histologically proven N2 disease (Table 1).
When the US data was added to the cTNM staging, no
differences were identified in nodal disease assessment.
Agreement on anatomical sites between cTNM and
pTNM, as well as kappa scores, are highlighted in Table
2. The agreement between cTNM (without US) and
pTNM when assessing the tongue was 95.7%, FOM
86.6%, buccal mucosa 82.9%, retromolar area 75.0% and
tonsils 91.7%. This may be due to the fact that deep and
posterior oral structures are a challenge during clinical
examination as well as the dental artifacts that could
arise during scanning which affects staging of peri-den-
tal tumours (Table 2).
Overall the agreement between the 2 systems per 1
site was 86.60% (Kappa agreement = 0.80), per 2 sites
90.0% (Kappa agreement = 0.68) and per 3 sites 90.48%
(Kappa agreement 0.6182), (Table 2).
Discussion
Cancers of the oral cavity and oro-pharyngeal region are
the sixth most common cancers in the world. Unfortu-
nately the incidence continues to rise with moderate
survival rates, despite the recent advances in surgery
and radiotherapy [9-11]. Oral squamous cell carcinoma
(OSCC) continues to affect more males than females
with a ratio of 1.5-1. Diagnosis is usually at the fifth or
sixth decade of life. However there is increase in the
trend of oral cancer affecting young people under the
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been found to be higher in ethnic minorities in other
developed countries [9-11]. The most common oral sites
to be affected with SCC include the lateral border of the
tongue, ventral tongue and floor of mouth. In the Asian
population, the buccal mucosa is commonly affected
due to betel quit/tobacco chewing habits [9-11].
The tumour size is one of the most important factors
affecting prognosis. This usually affects the clinician’s
ability to decide between ablative surgery, radiotherapy,
chemotherapy, photodynamic therapy or just proceed to
palliative care which could include a combination of any
of the above therapies. Also, it is well documented that
increased tumour size is related to local and regional
disease spread, higher recurrence rates and poor prog-
nosis [11-15].
Loco-regional spread to the cervical chain complicates
treatment options and worsen the outcome. Several fac-
tors have been known to influence local and regional
tumour spread to the lymphatics and they include
tumour primary site and thickness, double DNA aneu-
ploidy, poorly differentiated tumours, infiltrating-type
invasive front and perineural and peri/endovascular
invasion. Distant tumour spread occurs most commonly
in uncontrolled local and regional disease and nodal dis-
ease [11-15].
The influence of the histological grading as a prognos-
tic factor in oral squamous cell carcinoma have been
assessed in several studies and found to be a significant
predictor of local and regional failure as well as tumour
recurrence. Positive close tumour margins are usually
associated with high risk of local recurrence and have a
negative effect on survival [11-15].
An accurate clinical staging is of an utmost importance.
It is the corner stone in which the surgical team build the
surgical treatment plan and decide whether an adjuvant
therapy is required to deal with any possible problem that
might arise (i.e. impossible to achieve negative margins
near vital neurovascular structure or managing distant dis-
ease causing pulmonary haemorrhage prior to surgery).
The failure to achieve an accurate staging may lead to
incomplete surgical planning and hence unforeseen pro-
blems that may adversely affect the patient, leading to
higher morbidity and mortality.
It is debatable that inaccurate registration of nodal
involvement during the clinical TNM staging is unlikely
to affect the patient’s prognosis. Histo-pathological
Table 1 The cTNM and the pTNM staging of the cohort involved in this study
cTNM (with no US) Frequency (%) pTNM
Frequency (%)
Tumour size underestimated Nodal disease missed
T1N0M0 107 (43.7) 96 (39.2) 2 (T2) 5 (N1), 3 (N2)
T2N0M0 36 (14.7) 32 (13.1) 1 (T3) 5 (N1), 1 (N2)
T3N0M0 20 (8.2) 18 (7.3) 2 (T4) 1 (N1)
T4N0M0 45 (18.4) 42 (17.1) - 4 (N1), 1 (N2)
T1N1M0 10 (4.1) 13 (5.3) 2 (T2)
T2N1M0 12 (4.9) 16 (6.5) 1 (T3) 1 (N2)
T3N1M0 9 (3.7) 10 (4.1) - 2 (N2)
T4N1M0 6 (2.4) 10 (4.1) - -
T1N2M0 0 (0.0) 3 (1.2) - -
T2N2M0 0 (0.0) 2 (0.8) - -
T3N2M0 0 (0.0) 2 (0.8) - -
T4N2M0 0 (0.0) 1 (0.4) - -
The table also identifies the number of patients with underestimated tumour size and missed nodal disease
Table 2 Agreement on anatomical sites between cTNM
and pTNM, as well as kappa scores
Total Agreement Kappa Std. Err of
kappa
Primary Tongue 47 95.74% 0.94 0.07
FOM 82 86.59% 0.82 0.05
Retromolar
area
12 75.00% 0.69 0.12
Buccal
mucosa
70 82.86% 0.77 0.06
Lower lip 7 85.71% 0.79 0.20
Gingiva 7 85.71% 0.81 0.20
Hard palate 3 100.00% 1.00 0.58
Soft palate 4 100.00% 1.00 0.36
Tonsils 12 91.67% 0.88 0.17
Overall 245 87.35% 0.83 0.03
Secondary Tongue 12 75.00% 0.00 0.00
FOM 15 100.00% 1.00 0.26
Gingiva 16 93.75% 0.82 0.25
Tonsils 3 66.67% 0.00 -
Tertiary Buccal
mucosa
6 100.00% 1.00 0.41
Gingiva 7 71.43% 0.00 0.00
Per 1 site - 194 86.60% 0.80 0.04
Per 2 sites - 30 90.00% 0.68 0.16
Per 3 sites - 21 90.48% 0.62 0.20
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undergo an adjuvant therapy (i.e. radiation) that would
be delivered anyway in the postoperative phase.
In this short communication, we highlighted the sig-
nificant differences between cTNM and pTNM when
US is not used in assessing for cervical nodal disease.
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